Pharming Announces Positive Data from Phase II/III Leniolisib Trial for The Treatment of Activated PI3K Delta Syndrome
Pharming Group N.V. announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a primary immunodeficiency disease. Principal Investigator V. Koneti Rao, M.D., a staff physician at the National Institutes of Health in Bethesda, Maryland, shared the findings in a presentation at the Clinical Immunology Society (CIS) 2022 Annual Meeting.